A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

Big Pharma spends millions of dollars on federal lobbying to protect its interests and prevent fair competition in the ...

Discover key insights from West Pharmaceutical Services' Q4 2024 earnings call, highlighting growth in GLP-1 elastomers, biologics, and HVP components.

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

As part of NJBIZ’s latest virtual discussion, business leaders in New Jersey weighed in on what to expect in the first 100 ...

Insider buying surged in February. Warren Buffett continues to build a stake in a media stock, and IPOs tempted some insiders ...